Prometheus Biosciences Statistics Share Statistics Prometheus Biosciences has 47.81M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 47.81M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 33.23M Failed to Deliver (FTD) Shares 43 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 5.9M, so 0% of the outstanding
shares have been sold short.
Short Interest 5.9M Short % of Shares Out n/a Short % of Float 15.72% Short Ratio (days to cover) 5.86
Valuation Ratios The PE ratio is -31.52 and the forward
PE ratio is null.
Prometheus Biosciences's PEG ratio is
-1.46.
PE Ratio -31.52 Forward PE n/a PS Ratio 656.18 Forward PS n/a PB Ratio 6.61 P/FCF Ratio -35.47 PEG Ratio -1.46
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Prometheus Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 31.04,
with a Debt / Equity ratio of 0.04.
Current Ratio 31.04 Quick Ratio 31.04 Debt / Equity 0.04 Debt / EBITDA -0.2 Debt / FCF -0.23 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $70.2K Profits Per Employee $-1.46M Employee Count 97 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is -0.49, so Prometheus Biosciences's
price volatility has been lower than the market average.
Beta -0.49 52-Week Price Change n/a 50-Day Moving Average 184.19 200-Day Moving Average 109.6 Relative Strength Index (RSI) 84.04 Average Volume (20 Days) 1,217,911
Income Statement In the last 12 months, Prometheus Biosciences had revenue of 6.81M
and earned -141.75M
in profits. Earnings per share was -3.49.
Revenue 6.81M Gross Profit 6.81M Operating Income -145.78M Net Income -141.75M EBITDA -145.78M EBIT -145.78M Earnings Per Share (EPS) -3.49
Full Income Statement Balance Sheet The company has 292.42M in cash and 29.54M in
debt, giving a net cash position of 262.88M.
Cash & Cash Equivalents 292.42M Total Debt 29.54M Net Cash 262.88M Retained Earnings -331.09M Total Assets 758.41M Working Capital 707.06M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -123.25M
and capital expenditures -2.7M, giving a free cash flow of -125.96M.
Operating Cash Flow -123.25M Capital Expenditures -2.7M Free Cash Flow -125.96M FCF Per Share -3.1
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -2140.96% and -2081.83%.
Gross Margin 100% Operating Margin -2140.96% Pretax Margin -2081.83% Profit Margin -2081.83% EBITDA Margin -2140.96% EBIT Margin -2140.96% FCF Margin -1849.86%
